Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14887643 | 0.93 | SMN1; SMN2 (0.40) | HTTLMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL16017403 | 0.93 | HTT (0.45) | HTTLMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL14887640 | 0.90 | RAB9A (0.47) | HTTSMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL16017399 | 0.89 | SMN1; SMN2 (0.43) | HTTLMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL16017397 | 0.89 | LMNA (0.46) | HTTLMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL14887633 | 0.88 | BUB1 (0.41) | HTTLMNASMN1; SMN2MAPTPOLB | |
| SCHEMBL14887631 | 0.86 | ITGB1 (0.42) | HTTLMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL14887635 | 0.86 | SMN1; SMN2 (0.39) | HTTLMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL16017406 | 0.85 | MEN1 (0.47) | HTTLMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL14887630 | 0.83 | GRM4 (0.41) | HTTLMNASMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | HTT 809/4885LMNA 1306/4885SMN1; SMN2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.